Suncoast Equity Management Trimmed Check Point (CHKP) Holding By $617,400, Navidea Biopharmaceuticals (NYSEMKT:NAVB) Shorts Lowered By 2.93%

May 30, 2017 - By Richard Conner

Suncoast Equity Management decreased Check Point (CHKP) stake by 5.54% reported in 2016Q4 SEC filing. Suncoast Equity Management sold 7,350 shares as Check Point (CHKP)’s stock rose 7.13%. The Suncoast Equity Management holds 125,244 shares with $10.58M value, down from 132,594 last quarter. Check Point now has $18.54 billion valuation. The stock rose 0.64% or $0.71 reaching $111.92. About 54,587 shares traded. Check Point Software Technologies Ltd. (NASDAQ:CHKP) has risen 31.64% since May 30, 2016 and is uptrending. It has outperformed by 14.94% the S&P500.

Navidea Biopharmaceuticals Incorporated (NYSEMKT:NAVB) had a decrease of 2.93% in short interest. NAVB’s SI was 13.12 million shares in May as released by FINRA. Its down 2.93% from 13.51 million shares previously. With 503,900 avg volume, 26 days are for Navidea Biopharmaceuticals Incorporated (NYSEMKT:NAVB)’s short sellers to cover NAVB’s short positions. The SI to Navidea Biopharmaceuticals Incorporated’s float is 9.83%. It is 0.00% or $0 reaching $0.45 per share. It is down 47.35% since May 30, 2016 and is downtrending. It has underperformed by 64.05% the S&P500.

Analysts await Check Point Software Technologies Ltd. (NASDAQ:CHKP) to report earnings on July, 25. They expect $1.10 earnings per share, up 13.40% or $0.13 from last year’s $0.97 per share. CHKP’s profit will be $182.22M for 25.44 P/E if the $1.10 EPS becomes a reality. After $1.10 actual earnings per share reported by Check Point Software Technologies Ltd. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Among 21 analysts covering Check Point Software Technologies Ltd. (NASDAQ:CHKP), 6 have Buy rating, 2 Sell and 13 Hold. Therefore 29% are positive. Check Point Software Technologies Ltd. had 28 analyst reports since September 10, 2015 according to SRatingsIntel. The rating was initiated by Evercore with “Hold” on Tuesday, December 15. As per Thursday, September 10, the company rating was initiated by BTIG Research. Wunderlich reinitiated Check Point Software Technologies Ltd. (NASDAQ:CHKP) on Tuesday, September 13 with “Hold” rating. The firm has “Underweight” rating given on Wednesday, January 6 by Barclays Capital. The stock has “Sector Perform” rating by RBC Capital Markets on Tuesday, January 17. The firm has “Overweight” rating given on Friday, January 20 by First Analysis. PiperJaffray initiated the shares of CHKP in report on Wednesday, September 28 with “Overweight” rating. Bernstein initiated the stock with “Underperform” rating in Friday, March 11 report. UBS maintained the shares of CHKP in report on Thursday, April 21 with “Neutral” rating. The rating was downgraded by Deutsche Bank on Thursday, June 16 to “Hold”.

Investors sentiment increased to 0.72 in Q4 2016. Its up 0.33, from 0.39 in 2016Q3. It is positive, as 6 investors sold Navidea Biopharmaceuticals Inc shares while 12 reduced holdings. 5 funds opened positions while 8 raised stakes. 13.64 million shares or 1.81% less from 13.89 million shares in 2016Q3 were reported. Stratos Wealth Ptnrs Limited holds 45,470 shares. Alexandria Cap Ltd Llc has invested 0% in Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB). 27,760 are owned by Cambridge Invest Inc. Two Sigma Securities Ltd Liability Corp stated it has 26,823 shares. Kcg holds 15,086 shares. 173,782 are owned by Morgan Stanley. Northern Trust holds 0% of its portfolio in Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) for 224,558 shares. Price T Rowe Assoc Md holds 0% of its portfolio in Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) for 70,000 shares. D E Shaw And Communications Incorporated owns 244,395 shares. Blackrock Inv Mgmt Ltd Liability Company accumulated 27,075 shares. Manufacturers Life Insurance The has invested 0% in Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB). Blackrock accumulated 0% or 1 shares. Bailard Inc has invested 0% in Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB). Susquehanna Interest Llp invested in 26,101 shares. 90,315 are owned by Sii Investments Wi.

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical firm focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company has market cap of $72.85 million. The Firm is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. It currently has negative earnings. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages.